AU4844101A - Use of aliphatic quaternary ammonium as adjuvant in a pharmaceutical compositionadministered by mucosal delivery - Google Patents

Use of aliphatic quaternary ammonium as adjuvant in a pharmaceutical compositionadministered by mucosal delivery

Info

Publication number
AU4844101A
AU4844101A AU48441/01A AU4844101A AU4844101A AU 4844101 A AU4844101 A AU 4844101A AU 48441/01 A AU48441/01 A AU 48441/01A AU 4844101 A AU4844101 A AU 4844101A AU 4844101 A AU4844101 A AU 4844101A
Authority
AU
Australia
Prior art keywords
compositionadministered
adjuvant
pharmaceutical
quaternary ammonium
mucosal delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU48441/01A
Inventor
Christine Klinguer-Hamour
Dominique Velin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of AU4844101A publication Critical patent/AU4844101A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU48441/01A 2000-03-31 2001-04-02 Use of aliphatic quaternary ammonium as adjuvant in a pharmaceutical compositionadministered by mucosal delivery Abandoned AU4844101A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0004120 2000-03-31
FR0004120A FR2806913B1 (en) 2000-03-31 2000-03-31 USE OF ALIPHATIC QUATERNARY AMMONIUMS AS ADJUVANT IN A MUCOSAL ADMINISTRATIVE PHARMACEUTICAL COMPOSITION
PCT/FR2001/000984 WO2001074387A1 (en) 2000-03-31 2001-04-02 Use of aliphatic quaternary ammonium as adjuvant in a pharmaceutical composition administered by mucosal delivery

Publications (1)

Publication Number Publication Date
AU4844101A true AU4844101A (en) 2001-10-15

Family

ID=8848716

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48441/01A Abandoned AU4844101A (en) 2000-03-31 2001-04-02 Use of aliphatic quaternary ammonium as adjuvant in a pharmaceutical compositionadministered by mucosal delivery

Country Status (4)

Country Link
EP (1) EP1267923A1 (en)
AU (1) AU4844101A (en)
FR (1) FR2806913B1 (en)
WO (1) WO2001074387A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
EP0625207A1 (en) * 1991-12-17 1994-11-23 The Regents Of The University Of California Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
US5951988A (en) * 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US5773011A (en) * 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
KR19980067138A (en) * 1997-01-31 1998-10-15 박원훈 Fat emulsions for efficiently delivering genes or biologically active drugs into cells and methods for preparing the same
US6271200B1 (en) * 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
WO2000069458A2 (en) * 1999-05-12 2000-11-23 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
DE60016205T2 (en) * 1999-05-28 2005-12-01 Vical, Inc., San Diego CYTOFECTIN DIMERS AND METHOD FOR THEIR USE
EP1217975A1 (en) * 1999-09-08 2002-07-03 Watson Pharmaceuticals, Inc. Using quaternary ammonium salts for transdermal drug delivery
EP1223979A1 (en) * 1999-10-26 2002-07-24 ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. Adjuvants for nucleic acid vaccines

Also Published As

Publication number Publication date
FR2806913A1 (en) 2001-10-05
WO2001074387A1 (en) 2001-10-11
FR2806913B1 (en) 2003-01-31
EP1267923A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
GB0302218D0 (en) Vaccine formulation & Mucosal delivery
AU2002227910A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
PL392363A1 (en) Vaccine formulation
AU2002239397A1 (en) Drug formulation having improved oral tolerability
AU2001280908A1 (en) Rotavirus vaccine formulations
AU2001258117A1 (en) Supports for photosensitizer formulations
AU2001260455A1 (en) Cyclic amino acid derivatives useful as pharmaceutical agents
AU2001258279A1 (en) Adjuvant for vaccines
AU2001289102A1 (en) Topical formulations for delivery of interleukin-11
AU2001259472A1 (en) Aqueous adhesive formulations
GB2360210B (en) Sublingual vaccine formulation
AU2001275286A1 (en) Transdermal delivery
AU2003282498A1 (en) Hiv vaccine formulations
AU2002210407A1 (en) Therapeutic vaccine formulations containing chitosan
AU2001258550A1 (en) Insulin formulation for inhalation
AU2001232017A1 (en) Pharmaceutical composition for pulmonary delivery
AU2003229199A1 (en) Liposome vaccine formulations for fin-fish
AU4445201A (en) Method for administering insulin to the buccal region
IL152533A0 (en) NOVEL FORMULATIONS OF alpha-2,4-DISULFOPHENYL-N-TERTBUTYLNITRONE
HUP0600143A2 (en) A stable pharmaceutical formulation comprising torsemide modification ii
AU2001278323A1 (en) Modified sialic acid vaccines
AU4844101A (en) Use of aliphatic quaternary ammonium as adjuvant in a pharmaceutical compositionadministered by mucosal delivery
AU2002242142A1 (en) A cytokine related structurally to il-17
AU2001263164A1 (en) Flexible job delivery for job preparation
GB0014851D0 (en) Novel pharmaceutical formulation

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase